ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary R&D platform of Pharnext is based on network pharmacology. It allows the development of synergistic combinations of repositioned drugs – pleodrugs – which benefit from an outstanding safety profile and IP with strong enforceability. The company’s two lead pleodrugs are PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (Phase 3 ongoing) and PXT864 for Alzheimer’s disease (Phase 2a ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).

PLEO-CMT STUDY

THE INTERNATIONAL PIVOTAL PHASE 3 STUDY OF PXT3003 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A IS ONGOING.
If you would like more information about this clinical trial, please visit the following websites:
For France: CMT France - http://www.cmt-france.org
For other European countries: OrphanDev - http://www.orphan-dev.org
For the US: Hereditary Neuropathy Foundation (HNF) - http://www.hnf-cure.org
Worldwide: ClinicalTrials - https://clinicaltrials.gov

LATEST NEWS
Monday, 25 April 2016

First US study site activated for PXT3003 Phase 3 trial

Press Release (EN or FR)

Monday, 22 February 2016

N Murphy and P Schwich appointed as CSO & CFO

Press Release (EN or FR)

Tuesday, 16 February 2016

Pharnext supports the fight against rare diseases

Press Release (EN or FR)

Tuesday, 26 January 2016

OrphanDev Collaboration for CMT Phase III Trial

Press Release (EN or FR)